Clearance of 25-hydroxyvitamin D in Cystic Fibrosis
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to define 25(OH)D3 catabolism in CF patients using gold standard
pharmacokinetics studies. Specifically, the investigators will evaluate the metabolic
clearance of 25(OH)D3 among participants with CF and matched control subjects. The goal of
this work is to provide the first comprehensive characterization of vitamin D metabolism in
CF patients and promote novel hypotheses for subsequent studies.
Phase:
Phase 1
Details
Lead Sponsor:
University of Washington
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)